GlobeNewsWire
12 Sept 2026, 18:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' drug candidate leads to direct loss of future revenue streams and significant market cap erosion.
-0.90A securities class action lawsuit has been filed alleging Regeneron misled investors regarding the trial's progress and delayed disclosing protocol changes. — Legal proceedings create ongoing financial liability and reputational risk, though the primary price drop was driven by the trial failure.
-0.40The failure of the melanoma therapy trial resulted in an estimated $11 billion wipeout of Regeneron's market capitalization. — This quantifies the realized negative market reaction, confirming the high material value investors placed on this specific drug candidate.
-0.20Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
The company is facing a class action lawsuit following a failed Phase 3 clinical trial and a significant market capitalization loss.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
